| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2023―Nov―06 |
Letter to the Editor: Repurposing Tafenoquine as a Potential Inhibitor Against Severe Acute Respiratory Syndrome Coronavirus 2 Main Protease via a Fluorescence Polarization Assay |
Rui Zhang, Haohao Yan, Gangan Yan, Xiaoping Liu, Yunyu Chen |
| 2 |
[GO] |
2022―Jan―06 |
Repurposing of Hydroxyurea Against COVID-19: A Promising Immunomodulatory Role |
Moayed Ben Moftah, Asma Eswayah |
| 3 |
[GO] |
2021―Aug―31 |
Re: “Letter to the Editor: Repurposing of an Antisepsis Drug in COVID-19 Patients,” by Kumar et al. (doi: 10.1089/adt.2020.994) |
Rajni Rani |
| 4 |
[GO] |
2021―Mar―17 |
Cefaclor Monohydrate-Loaded Colon-Targeted Nanoparticles for Use in COVID-19 Dependent Coinfections and Intestinal Symptoms: Formulation, Characterization, Release Kinetics, and Antimicrobial Activity |
A. Alper Öztürk, İrem Namlı, Abdurrahman Aygül |
| 5 |
[GO] |
2020―Nov―09 |
Individuating Possibly Repurposable Drugs and Drug Targets for COVID-19 Treatment through Hypothesis-Driven Systems Medicine Using CoVex |
Julian Matschinske, Marisol Salgado-Albarrán, Sepideh Sadegh, Dario Bongiovanni, Jan Baumbach, David B. Blumenthal |
| 6 |
[GO] |
2020―Jun―18 |
COVID-19 and the Drug Repurposing Tsunami |
Hermann A.M. Mucke |
| 7 |
[GO] |
2020―Jun―04 |
Letter to the Editor: Repurposing of an Antisepsis Drug in COVID-19 Patients |
Ashutosh Kumar, Vikas Pareek, Kamla Kant |
